Full-Year Financial Summary for the Third Quarter of FY2026 (Japanese GAAP) (Consolidated)

Performance Overview

For the third quarter of the fiscal year ending March 2026, consolidated results were net sales of 79.204 billion yen (5.1% increase YoY), operating income of 9.435 billion yen (12.4% increase YoY), ordinary income of 9.723 billion yen (12.2% increase YoY), and net income attributable to owners of the parent of 6.715 billion yen (12.4% increase YoY). Amid continued uncertainty in the domestic and international business environment, the company advanced measures such as strengthening the hub functions of wholesale operations, digitalization, labor-saving initiatives, and expanding logistics capacity. Contributions to performance were driven by expanding product offerings in the product database, strengthening inventory coordination, expanding connections of the centralized purchasing system, increasing end-user registrations in the sales support e-commerce system, and relocating and newly establishing the Kyushu distribution center.

Sales by Segment and Progress of Medium-Term Management Plan

Segment sales were 66.616 billion yen (6.8% increase YoY) in the Lab & Industry segment, 12.164 billion yen (3.1% decrease YoY) in the Medical segment, and 0.423 billion yen (5.2% decrease YoY) in Others. In the Lab & Industry segment, while facing delays in research and development investment at universities and trends of export companies, growth in e-commerce contributed positively. The Medical segment addressed ongoing cost containment and purchasing restraint in healthcare through strengthened sales activities targeting newly established clinics. The key sales initiatives in the medium-term management plan 'FY2025-27' proceeded generally smoothly, with e-commerce sales increasing 110.7% YoY and web-only products up 110.0% YoY.